USmacro: Relevance of Ultrasound Screening for Foetal Macrosomia

Sponsor
CHU de Reims (Other)
Overall Status
Unknown status
CT.gov ID
NCT04443205
Collaborator
(none)
3,000
1
18
166.6

Study Details

Study Description

Brief Summary

Management of fetal macrosomia is based on a suspicion of macrosomia (no certainty before birth). This management is an artificial induction of labour for an earlier delivery and therefore a lower fetal weight gain. Several studies have already shown that ultrasound performed during the third trimester of pregnancy was not a perfect tool for this screening.

Condition or Disease Intervention/Treatment Phase
  • Other: Data record

Detailed Description

The aim of the study is to describe management of women whose child is macrosomal but has not been screened g using ultrasound during the third trimester of pregnancy.

Study Design

Study Type:
Observational
Anticipated Enrollment :
3000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Relevance of Ultrasound Screening for Foetal Macrosomia and Description of Its Management in Champagne-Ardenne
Anticipated Study Start Date :
Jun 1, 2020
Anticipated Primary Completion Date :
Sep 1, 2021
Anticipated Study Completion Date :
Dec 1, 2021

Arms and Interventions

Arm Intervention/Treatment
no macrosomy

pregnant women whose child is not macrosomal

Other: Data record
Data record

screened macrosomy

pregnant women whose child is macrosomal and have been screened g using ultrasound during the third trimester of pregnancy

Other: Data record
Data record

no screened macrosomy

pregnant women whose child is macrosomal and havenot been screened g using ultrasound during the third trimester of pregnancy

Other: Data record
Data record

Outcome Measures

Primary Outcome Measures

  1. Foetal macrosomia [Baseline]

    estimated weight above the 90th percentile of the curves of the French College of Fetal Ultrasound during the third trimester ultrasound

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion criteria : Patients (consecutive inclusions) :

Women pregnant Women followed in the gynaecology and obstetrics department of the CHU of Reims, the CHG of Charleville Mézières or the CHG of Chalons en Champagne.

Women for which the delivery is planned in the gynaecology and obstetrics department of the Reims University Hospital, the Charleville Mézières General Hospital or the Chalons en Champagne General Hospital.

Non-inclusion criteria Women without ultrasound dating scan in the first trimester. Women having a contraindication to labour or vaginal delivery Women with a scarred uterus Women having a history of shoulder dystocia or obstetric trauma Women having a history of urinary or fecal incontinence Women having a history of bad birth experience with high psychological impact Women with maternal pathologies (excluding gestational diabetes) Women whose fetus is breech Women with twin pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Damien JOLLY Reims France

Sponsors and Collaborators

  • CHU de Reims

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
CHU de Reims
ClinicalTrials.gov Identifier:
NCT04443205
Other Study ID Numbers:
  • PO20090
First Posted:
Jun 23, 2020
Last Update Posted:
Jun 23, 2020
Last Verified:
Jun 1, 2020
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by CHU de Reims
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 23, 2020